



Patient zero

and the new world of genomic medicine


Euan Ashley MRCP DPhil, FACC, FESC
 Director, Stanford Center for Inherited
 Cardiovascular Disease



The question

- 10 years since draft HGP
- 2 years since the “Year of the GWAS”
- Very little impact on clinical medicine
- But, sequencing is getting cheaper
- The number of genomes is set to rise
- What does a consultation look like in 5 years?

Year	Cost estimate	Technology
2001	\$300,000,000	Sanger (ABI)
2001	\$100,000,000	Sanger (ABI)
2007	\$10,000,000	Sanger (ABI)
2008	\$2,000,000	Roche (454)
2008	\$1,000,000	Illumina
2008	\$500,000	Illumina
2009	\$250,000	Illumina
2009	\$48,000	Roche
2010	\$15,000	Complete



The idea

What if everybody's genome was available
 in their medical record?



biotechnology

LETTERS

USA TODAY

Home News Travel Money Sports Life Tech

Technology Science & Space Step for Gadgets

U.S. professor sequences own genome in weeks

Published 01/10/2009 5:51 PM | Comments: 1019 | Recommended: 0

SAN FRANCISCO (AP) — It might not be long until there is a gene scanner in every doctor's office, as DNA sequencing becomes faster and cheaper.

A Stanford University professor reported Monday that he has sequenced his entire genome in a few weeks for under \$50,000 using a single machine.

Six years ago, hundreds of researchers at the Human Genome Project completed the same task for \$200 million. It took 13 years.

"It's continuing down the path to making it so every Tom, Dick and Harry are going to have their genomes sequenced," said Edouard Hohe, director of the U.S. Department of Energy Joint Genome Institute, who was not involved in the study.

The breakthrough pace of technological progress in the field of DNA sequencing has raised hopes that affordable gene scans will be available to all patients soon.

Researchers hope cheap gene sequencing will lead to highly customized disease prevention, diagnosis and treatment tailored to an individual's genetic code.


Only a handful of human genomes have been sequenced so far. Typically those scans have used several machines working side-by-side to read the four chemicals that make up a "letter" in the DNA sequence.

"We've shown it can be done with one machine and just three people, with just one operating the machine," said Stanford bioengineering professor Stephen Quake, whose results were published in the journal Nature Biotechnology on Monday.



Patient zero

- 40 year old male in good health presents to his doctor with his whole genome
- No symptoms
- Exercises regularly
- Takes no medication
- Family history of aortic aneurysm
- Family history of sudden death




Clinical examination


- Normal appearing male
- Comfortable at rest
- HS 1,2+0
- No murmurs, rubs or gallops
- Chest clear, abdomen nad
- Musculoskeletal, neuropsych examinations grossly normal
- Afebrile
- HR 60pm, BP 128/80



Electrocardiogram



Echocardiography



Exercise test

Test Date	09/04/2009		
Name (First Last)	MBN	11581501	
Referring MD	Esau Ashley	Diagnosis	Health care maintenance
Age (years)	40	Weight (lbs)	190
		Height (in)	71
Exercise mode	Bike	Protocol	Range (Actual exercise time: 10 min 9 secs)
	Rest	Max	
Heart rate (bpm)	76	191	% pred HR 106
VO ₂ (ml/kg/min)	3.5	49.6	% pred VO _{2max} 145
Systolic blood pressure (mmHg)	100	192	
O ₂ saturation (%)	99	99	
Respiratory exchange ratio	0.93	1.13	RER: 1.05 indicates adequate exercise challenge
Perceived exertion	=	17	Scale of 6 - 20 (13 = unstructured hard; 17 = very hard)
Ve VCO ₂ slope	26		-30 normal
Ventilatory threshold (%)	42		-14 is an adverse prognostic marker in the heart failure population
Heart rate recovery at 1 minute (bpm)	41		-13 beat drop at 1 minute is abnormal (normal, clinically untrained population); -6 beat drop at 1 minute is abnormal (lower fitness)
External work equivalent	4570kWh		
Breathing reserve			-20% suggest possible pulmonary limitation to exercise
ECG findings	Rhythmic sinus Anterior MI scar A 1.1 mm upslapping ST depression was seen in one region. Scar and/or lead averted during exercise. 1.5 mm upslapping ST depression noted in leads V4-V5, resolved immediately as recovery. Notes: Estimated cardiac output available separately.		



Musculature not to scale



Lab tests panel

WBC	4.9		Total bili	0.5
Hb	15.7		AST	25
Platelets	147		ALT	33
Na	143		ALP	93
K	4.0		Alb	4.2
BUN	20			
Cr	1.2		Cholesterol	218
eGFR			LDL	156
Ca	9.4		HDL	48
Fasting glucose	93		TG	68
			hsCRP	<0.2
			Lp(a)	114




Parsing
6,000,000,000
data
points


When one base pair
change can turn this



into this



The Teams



Clinical assessment incorporating a personal genome

Evan A Ashley, Atul J Butte, Matthew T Wheeler, Rong Chen, Teri E Klein, Frederick E Dewey, Joel T Dudley, Kelly E Ormond, Aleksandra Pavlovic, Alexander A Morgan, Dmitry Pushkarev, Norma F Neff, Louanne Hudgins, Li Gong, Laura M Hodges, Dorit S Berlin, Caroline F Thors, Katrin Sangkuhl, Joan M Hebert, Mark Woon, Hersh Sagreiya, Ryan Whaley, Joshua W Knowles, Michael F Chou, Joseph V Thakuria, Abraham M Rosenbaum, Alexander Wait Zaranek, George M Church, Henry T Greely, Stephen R Quake, Russ B Altman


Lancet 2010; 375: 1525-35

\$1000 Personal Genome Coming: Are We Ready?


WebMD • [Journal J. Dobson](#) - 18 hours ago
 April 29, 2010 - Do you really want to know all of the information encoded in your genes? A thought-provoking new study shows why you might - and why you might not. Stanford bioengineer explores own genome. [Gain Jobs](#)



Mercury News
[This man knows his genetic destiny](#) - BBC News
 Reuters - [The Guardian](#) - [BusinessWeek](#) - [The Associated Press](#)
[all 307 news articles](#) • [Email this story](#)



The (evolving) approach




Rare, novel and Mendelian variants



Rare/novel algorithm

- What does it mean for a variant to be associated with disease?
 - Cosegregation in a large kindred?
 - Early stop in key gene
 - in one proband? in several individuals?
 - Splice site mutation?
 - Novel mutation?
 - Not seen in ?how many ?controls
 - What's a control?



Rare variant databases

- Human Genome Mutation database
 - Public/professional
- Human Variome project
- Human genome variation database
- Private databases




ABC4	ATP-binding cassette transporter-related	Retina International
ABC8	ATP-binding cassette transporter-related	Retina International
ABC8	ATP-binding cassette transporter-related	Hopital Necker Enfants Malades (Paris), France
ABD01	ATP-binding cassette transporter-related	Academic Medical Center, Amsterdam, Holland and Kennedy Krieger Institute, Baltimore MD, USA
ABD	ATP-binding cassette transporter-related	Albert Einstein College of Medicine, New York, USA
ADCE	ATP-binding cassette transporter-related	Albert Einstein College of Medicine, New York, USA
ACTC	ATP-binding cassette transporter-related	Australian National Genetic Information Service
ACTC	ATP-binding cassette transporter-related	Harvard University, USA
ADVW11	ATP-binding cassette transporter-related	Heriot Watt University, Edinburgh, UK
ADK	ATP-binding cassette transporter-related	University of Tampere, Finland
ADK3	ATP-binding cassette transporter-related	Tel Aviv University, Israel
ADL	ATP-binding cassette transporter-related	University of Leuven Medical School, Belgium
ADL1	ATP-binding cassette transporter-related	Retina International
ALB	ATP-binding cassette transporter-related	Mary Imogene Bassett Hospital Research Institute, New York, USA
ALD181	ATP-binding cassette transporter-related	University of Colorado Health Sciences Centre, USA
ALDQ	ATP-binding cassette transporter-related	University of Colorado Health Sciences Centre, USA
ALDQAL	ATP-binding cassette transporter-related	University of Colorado Health Sciences Centre, USA
ALDQAL	ATP-binding cassette transporter-related	University of Colorado Health Sciences Centre, USA
ALDQ	ATP-binding cassette transporter-related	University of Colorado Health Sciences Centre, USA
ALDQ	ATP-binding cassette transporter-related	Boston University, USA
ALG6	ATP-binding cassette transporter-related	Leuven University, Belgium
ALPL	ATP-binding cassette transporter-related	University of Versailles Saint Quentin en Yvelines, France
ANBKA	ATP-binding cassette transporter-related	University of North Carolina, USA
AP01	ATP-binding cassette transporter-related	University of Minnesota, USA
APC	ATP-binding cassette transporter-related	Mayo Clinic, USA
APC	ATP-binding cassette transporter-related	Institut Curie (Paris), France
APC	ATP-binding cassette transporter-related	Tel Aviv University, Israel
APP	ATP-binding cassette transporter-related	Antwerp University, Belgium
APQ5	ATP-binding cassette transporter-related	Albert Einstein College of Medicine, New York, USA
APQ5	ATP-binding cassette transporter-related	Albert Einstein College of Medicine, New York, USA
APQ5	ATP-binding cassette transporter-related	McGill University (Quebec), Canada
AR	ATP-binding cassette transporter-related	McGill University (Quebec), Canada
AT3	ATP-binding cassette transporter-related	Imperial College School of Medicine, London, UK
ATN	ATP-binding cassette transporter-related	Virginia Mason Research Center (Seattle), USA
ATP7B	ATP-binding cassette transporter-related	University of Alberta, Canada
ATP7B	ATP-binding cassette transporter-related	Tel Aviv University, Israel
AP	ATP-binding cassette transporter-related	McGill University (Quebec), Canada
APW2	ATP-binding cassette transporter-related	McGill University (Quebec), Canada

Private mutation databases

http://www.hgmd.ac.uk/docs/oth_mut.html
Accessed 3/11/2010





Algorithms for entirely novel variants

SIFT

SIFT predicts whether an amino acid substitution affects protein function based on sequence homology and the physical properties of amino acids. SIFT can be applied to naturally occurring polymorphisms and laboratory-induced missense mutations.

Category	Tool	Description
1. Select to coding variants	Protein domain	Exclude coding variants from a large list of genomic variants
2. SIFT missense single nucleotide variants	Protein domain	Provide SIFT predictions for variants with genome coordinates
3. SIFT missense multiple nucleotide variants	Protein domain	Provide SIFT predictions for variants with genome coordinates
4. SIFT stop gain variants	Protein domain	Provide SIFT predictions for variants with genome coordinates
5. SIFT stop loss variants	Protein domain	Provide SIFT predictions for variants with genome coordinates
6. SIFT indel variants	Protein domain	Provide SIFT predictions for variants with genome coordinates
7. SIFT splice site variants	Protein domain	Provide SIFT predictions for variants with genome coordinates
8. SIFT 3D structure variants	Protein domain	Provide SIFT predictions for variants with genome coordinates
9. SIFT 3D structure variants	Protein domain	Provide SIFT predictions for variants with genome coordinates
10. SIFT 3D structure variants	Protein domain	Provide SIFT predictions for variants with genome coordinates

PolyPhen

PolyPhen (Polymorphism Phenotyping) is a tool which predicts possible impact of an amino acid substitution on the structure and function of a human protein using sequence homology and structure information.

Monday, August 24, 2009

Genetic polymorphisms have been shown to affect drug response in humans. Some examples of PolyPhen variants are provided below to illustrate the tool's predictions.

Tuesday, August 12, 2009

Genetic polymorphisms have been shown to affect drug response in humans. Some examples of PolyPhen variants are provided below to illustrate the tool's predictions.

Monday, August 24, 2009

Genetic polymorphisms have been shown to affect drug response in humans. Some examples of PolyPhen variants are provided below to illustrate the tool's predictions.

Polygenic disease – what we have now

STANFORD SCHOOL OF MEDICINE

ATP III Guidelines At-A-Glance Quick Desk Reference

Step 1: Determine lipoprotein levels-obtain complete lipoprotein profile after 9- to 12-hour fast.

ATP III Classification of LDL, Total, and HDL Cholesterol (mg/dL)

LDL Cholesterol - Primary target of therapy	Optimal
<100	Optimal
100-129	Near optimal/borderline optimal
130-159	Borderline high
160-199	High
≥200	Very high

Total Cholesterol

Optimal	Borderline high	High
<200	Borderline high	High
200-239	High	Very high
≥240	Very high	Very high

HDL Cholesterol

Optimal	Borderline low	Low	Very low
≥60	Borderline low	Low	Very low
40-59	Low	Very low	Very low
<40	Very low	Very low	Very low

Step 2: Identify presence of clinical atherosclerotic disease that confers high risk for coronary heart disease (CHD) even if CHD risk equivalent:

- Clinical CHD
- Symptomatic carotid artery disease
- Peripheral arterial disease
- Abdominal aortic aneurysm

Step 3: Determine presence of major risk factors (other than LDL):

Major Risk Factors (Excludes of LDL Cholesterol) That Modify LDL Goals:

- Cigarette smoking
- Hypertension (BP ≥160/90 mmHg or on antihypertensive medication)
- Low HDL cholesterol (<40 mg/dL)
- Diagnosed history of peripheral CHD or CHD in male first degree relative <55 years, or in female first degree relative <65 years
- Age (men ≥45 years, women ≥55 years)

*HDL cholesterol ≥60 mg/dL counts as a "negative" risk factor in presence or absence of other major risk factors.

Note: In ATP III, diabetes is regarded as a CHD risk equivalent.

Step 4: If 2+ risk factors (other than LDL) are present without CHD or CHD risk equivalent, assess 10-year (short term) CHD risk (see Framingham table).

Three levels of 10-year risk:

- ≥20% — CHD risk equivalent
- 10-20%
- <10%

Step 5: Determine risk category:

- Establish LDL goal of therapy
- Determine need for therapeutic lifestyle changes (TLC)
- Determine need for drug considerations

LDL Cholesterol Goals and Outcomes for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories.

Risk Category	LDL Goal	LDL Level at Which to Consider Drug Therapy	LDL Level at Which to Consider Drug Therapy
CHD or CHD Risk Equivalent	<100 mg/dL	≥100 mg/dL	≥150 mg/dL
2+ Risk Factors	<130 mg/dL	≥130 mg/dL	≥160 mg/dL
0-1 Risk Factor*	<160 mg/dL	≥160 mg/dL	≥190 mg/dL

*Some authorities recommend use of LDL lowering drugs in the category of an LDL cholesterol <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Therapeutic use of drug should generally be guided by presence of LDL-C, TG, HDL-C, and/or triglyceride abnormalities. *If a patient has 1 or 2 risk factors, the 10-year CHD risk is considered.

†Amount of protein with 0-1 risk factor varies: 10-year risk <10%, 10-year protein risk assessment in people with 0-1 risk factor is not available.




Step 6: Initiate therapeutic lifestyle changes (TLC) if LDL is above goal.

LDL Features:

- TLC Diet
- Saturated fat - 7% of calories, cholesterol <200 mg/day
- Complex increased intake (includes fiber 20-25 g/day) and plant sterosterols
- Weight management
- Increased physical activity


NATIONAL INSTITUTES OF HEALTH
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE

STANFORD SCHOOL OF MEDICINE



Missing heritability

- Rare variants
- Structural variants
- Epigenetic phenomena
- Over-zealous bounding of FWER
- G-G interaction
- G-E interaction
- G-G-E interaction



Can we apply this to individual genomes?



One approach

THE NEW ENGLAND JOURNAL OF MEDICINE
ORIGINAL ARTICLE

Polymorphisms Associated with Cholesterol and Risk of Cardiovascular Events

Sekar Kathiresan, M.D., Ole Melander, M.D., Ph.D., Dragi Arsenovski, Ph.D., Candace Guiducci, B.S., Noel P. Burt, B.S., Charlotta Roos, M.Sc., Joel N. Hirschhorn, M.D., Ph.D., Göran Berglund, M.D., Ph.D., Bo Heesbeen, M.D., Ph.D., Leif Groop, M.D., Ph.D., David M. Absher, M.D., Ph.D., Christopher Newton-Cheh, M.D., M.P.H., and Marju Ochoa-Melander, Ph.D.




Table 3. Lipid Levels and Crude Incidence Rates of Cardiovascular Disease, According to Genotype Score.*

Variable	Genotype Score†						P for Trend		
	-6	-7	8	9	10	11			
LDL cholesterol (mg/dl)	152±41 (N=122)	152±37 (N=309)	158±38 (N=574)	159±38 (N=894)	163±37 (N=913)	165±38 (N=726)	168±41 (N=455)	171±36 (N=229)	2×10 ⁻¹⁴
HDL cholesterol (mg/dl)	60±16	57±14	56±14	55±14	53±14	53±14	51±13	51±13	3×10 ⁻¹⁴
Crude incidence rate per 1000 person-years	3.1	2.7	5.1	1.9	5.3	6.8	5.7	11.0	

* Plus-minus values are means ±SD. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. LDL denotes low-density lipoprotein, and HDL, high-density lipoprotein.
† The genotype score represents the number of unfavorable alleles (the allele associated with higher LDL cholesterol or lower HDL cholesterol) at each of nine SNPs. These nine SNPs were APOB rs608, APOE cluster rs4420638, HMGCR rs12654264, LDLR rs1529729, PCSK9 rs11591147, ABCG1 rs1390532, CETP rs1800775, LIPC rs1390538, and LPL rs128.



Challenges in applying results of GWAS to individual genomes

- Theoretical
 - Not enough variance explained
- Practical
 - Most NCBI databases are catalogs
 - Although sharing and making data publicly available (despite ethical concerns) remains routine, journals have not traditionally insisted on sufficient data for genome interpretation (standard is 'reproduce the expt' but even that often not met)
 - Even the GWAS catalogs do not contain sufficient data
 - Genotype frequencies
 - Strand direction variable, rarely reported
 - Chromosomal position changes with each genome build




Existing SNP databases are limited in resource and content

- NHGRI GWAS Catalog
 - 2,387 SNPs → 321 diseases, curated from 509 PubMed
 - Odds Ratio, but no genotypes
- NHLBI GWAS Catalog
 - 52,546 SNPs → 87 diseases, curated from 119 PubMed
 - p_value, no OR



Stanford genetic variation database




Field name	Description
Broad Phenotype	The general disease or phenotypic condition under study
Narrow Phenotype	Detailed description of the studied phenotype
D. S. disease	Diseases or phenotypic trait?
MESH heading	MESH heading of the studied disease
UMLS CUI	Manually curated UMLS CUI for the disease
ChEMBL	Chemical used in study? Inhibitor, substrate, or not?
Significance	Whether the association was reported as significant in the literature
Study ID	An internal identifier to distinguish multiple studies in one literature
P-value	P-value of the association
Model	The genetic model used to calculate the p-value, such as additive, multiplicative, recessive, or dominant
Odds ratio	The odds ratio, relative risk, or hazards ratio of disease association between two comparing genotypes or alleles
OR-CI	95% confidence interval of the odds ratio
Comparison	Two genotypes or alleles used to calculate the odds ratio
Total sample size	Sum of patients in the case and control groups or the cohort size
Case/affected	Description of the patients in the case group
Controls/unaffected	Description of the patients in the control group
Cohort	Description of the patients in the cohort
Gender	The gender of the studied patients
Population	The ethnic group of the studied patients
Major/minor alleles	The major/minor alleles of the SNP
Strand direction	The strand direction was determined by comparing the major/minor alleles in the literature with the major/minor alleles in a similar population in the Hapmap project
Risk allele	The allele susceptible to disease
Single SNP/haplotype	Was the association studied for single SNP or haplotype?
Interaction	Was the association studied for gene-environmental interactions?
GWAS	GWAS or candidate gene/SNP study
PubMed	PubMed ID of the publication
Method	Genotyping technology, such as Taqman or Affymetrix 5.0
Comment	Comments from curators
Status	Review status of the entry

Rong Chen,
Atul Butte



Ways to apply this for genomic medicine




b= type 1 error
c= type 2 error

Parameter	expression
Sensitivity	$a/a+c$
Specificity	$d/d+b$
Prevalence	$a+b+c+d$
NPV	$d/d+c$
PPV	$a/a+b$
OR	$(a/b) / (c/d)$
OR	ad/cb
RR	$(a/a+b) / (c/c+d)$
LR+	$sen/1-spec$
LR-	$1-sen/spec$



Odds are....the effect will appear exaggerated


- Two groups (n=100), two conditions
- First group Y=80, N=20
- Second group Y=20, N=80
- First group is 4x more likely to be Y
- However, $OR = (80/20) / (20/80) = 16$
- This can be even more extreme
 - eg $(90/10) / (10/90)$, $OR=81!$
- Remember that for GWAS, most OR are in the range 1.3-1.6
- $60/40$ vs $50/50 = 1.5$



The Likelihood is . . . you will at least account for group-wise frequency characteristics

- The LR is easily overlaid on the pre-probability to provide a post-test probability
- This helps with the “relative risk” problem

Parameter	Expression
Pre test probability	Prevalence
Pre test odds	Prev/1-prev
Post test odds	Pre-test odds x LR
Post test probability	Post test odds / post test odds +1




Fagan TJ. Nomogram for Bayes theorem. *N Engl J Med.* 1975; 31:293(5):257.

Alex Morgan, Atul Butte




Riskogram methods and figure

- Pre test prob from various sources
 - Prevalence usually (matched to age, sex, ethnicity if possible)
 - Lifetime risk occasionally
- Mean LR when multiple studies for same SNP
 - Weighted mean (square root of sample size)
- Only one SNP per haplotype block (largest LR)
- Pre test odds multiplied by LRs cumulatively
 - Presented in decreasing order of studies, then sample size




Report card




Challenges

- Calls were made vs human reference sequence
 - Risk alleles in human reference sequence
- Winner's curse
 - Literature bias towards positive results
- Negative studies need to be included in algorithm
- Data for LR only available for 40% papers



Gene environment interaction




Joel Dudley, Atul Butte




What of "patient" zero?

- SQ feedback
 - PGx information welcome
 - Approach to personal and family screening
- Medical advice
 - Personal and family screening
 - CAD risk
 - ATP3+LPA+LR+PGx +clinical judgement
 - Rx statin






Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease




NATURE GENETICS VOLUME 43 | NUMBER 4 | APRIL 2011



FAMILY ZERO



Inheritance state analysis



Rick Dewey



Variant type	All variants		All rare/novel		Rare/novel and OMIM-disease associated gene	
	HG19 reference (n = 4302405)	CEU reference (n = 3732299)	HG19 reference (n = 351555)	CEU reference (n = 354074)	HG19 reference	CEU reference
Coding-missense	9468	7982	1276	1276	203	200
Coding-nonsense	52	50	13	13	1	1
Coding-synonym	11683	9928	1061	1059	186	186
Intronic	1303341	1128283	116276	115397	19544	19766
Splice-5'	156	147	16	16	0	0
Splice-3'	98	96	9	9	1	1
UTR-5'	40142	37794	3637	3619	510	516
UTR-3'	61826	59396	5989	5953	848	857
miRNA target	0	0	0	0	0	0
Pr-miRNA	2	2	1	1	0	0
Mature miRNA	0	0	0	0	0	0
Coding indels	1519	1476	432	412	73	71
Coding frameshift indels	440	418	273	253	29	27

Abbreviations: CEU reference, variant calls against CEU major allele reference; HG19 reference, variant calls against NCBI reference sequence 37.1; miRNA, micro RNA; Pr-miRNA, primary microRNA transcript; OMIM, Online Mendelian Inheritance in Man database; UTR, un-translated region.



SNP Location	Drug(s)	Drug(s) More Likely to Work	Drug(s) Less Likely to Work	Drug(s) More Likely to Cause Side Effect	Drug(s) Less Likely to Cause Side Effect	Drug Dose(s) Above Average	Drug Dose(s) Below Average	Drug Dose(s) Average	No PSX Action Phenotype Unknown	Confidence Level
rs9634438	warfarin	-	-	-	-	-	-	■●■○	-	High
rs1954787	citalopram	■●○	■	-	-	-	-	-	-	High
rs776746	cyclosporine	-	-	-	-	-	-	■●○	-	High
rs1800460	thiopurines	-	-	-	-	-	-	-	-	High
rs2108622	warfarin	-	-	-	-	-	-	■●○	-	Medium
rs4680	morphine	-	-	-	-	-	-	■●○	-	Medium
rs5443	statins	■●○	■○	-	-	-	-	-	-	Medium
rs4253778	beta blocking agents	○	■●	-	-	-	-	-	-	Medium
rs622342	metformin	○■	■	-	-	-	-	-	-	Medium
rs7569963	citalopram	-	-	■	■	-	-	-	○	Medium
rs8012562	ACE inhibitors	-	-	-	-	-	-	■●○	-	Low
rs11209716	ACE inhibitors	-	-	-	-	-	-	■	○	Low





Key: Father, Mother, Brother, Sister = ■●○



Chromosome	Gene	rsid	Affected family members	Disease	Inheritance	Onset: earliest	Onset: median	Severity	Actionability	Lifetime risk	Variant pathogenicity
12	VWF	rs6170615	■●○	Von Willebrand disease	Incomplete dominant	1	1	5	5	variable	7
10	HABP2	rs7080036	■●○	Coronoid stenosis, thrombophilia	AD	4	4	1	5	variable	7
19	SLC7A9	rs70389353	■●○	Cystinuria-kidney stones	AR	1	1	3	5	7	7
1	F5	rs6025	■●○	Thrombophilia	Incomplete dominant	4	4	4	5	2	7
1	MTHFR	rs1801133	■●○	Hyperhomocysteinemia	AR	1	1	1	6	2	7



Phasing



Rong Chen, Atul Butte



Conclusion



- In the future, we will not be limited by the availability of genetic information
- For medicine to become “personalized” we will need to learn how to parse this data

Acknowledgements

Patient Zero

Euan A Ashley, Atul J Butte, Matthew T Wheeler, Rong Chen, Teri E Klein, Frederick E Dewey, Joel T Dudley, Kelly E Ormond, Aleksandra Pavlovic, Alexander A Morgan, Dmitry Pushkarev, Norma F Neff, Louanne Hudgins, Li Gong, Laura M Hodges, Dorit S Berlin, Caroline F Thorn, Katrin Sangkuhl, Joan M Hebert, Mark Woon, Hersh Sagreya, Ryan Whaley, Joshua W Knowles, Michael F Chou, Joseph V Thakuria, Abraham M Rosenbaum, Alexander Wait Zaranek, George M Church, Henry T Greely, Stephen R Quake, Russ B Altman

Family Zero, also including

Pablo Cordero, Mike Snyder Carlos Bustamante, John West, Anne West, Konrad Karczewski, Jake Byrnes

